Telix Pharmaceuticals announced in the past week that it has upgraded its 2025 revenue guidance to a range of US$800 million to US$820 million, up from its prior forecast, and reported unaudited third...
Source LinkTelix Pharmaceuticals announced in the past week that it has upgraded its 2025 revenue guidance to a range of US$800 million to US$820 million, up from its prior forecast, and reported unaudited third...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.